Adcetris Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Low Dose Tailored-Field Radiation Therapy for Unfavorable Risk Pediatric Hodgkin Lymphoma

Trial Profile

Adcetris Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Low Dose Tailored-Field Radiation Therapy for Unfavorable Risk Pediatric Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Filgrastim; Prednisolone
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Apr 2015 Planned End Date changed from 1 Aug 2022 to 1 Apr 2025 as reported by ClinicalTrials.gov record.
    • 23 Apr 2015 Planned primary completion date changed from 1 Oct 2020 to 1 Aug 2021 as reported by ClinicalTrials.gov record.
    • 23 Apr 2015 Planned number of patients changed from 134 to 77 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top